Ann: Osteoarthritis pain reduced by Paradigms Zilosul (PPS), page-37

Well as much as i love this price increase on huge volume lately it surely needs a pullback or a breather. Problem is it's still undervalued as it is so any pullback would be shirt and sharp as eager buyers make the the most of panic sellers. The reason I believe so heartily that it is undervalued is if you compare it to tanezumab which was bought out for 2 billion usd and has since failed phase 2 trials and also the suite of drugs that Gilead paid 7.5 billion USD for which have some concerns around safety and their posistive effects are not well researched so far (pre phase 2 trials) then Zilosul which has passed phase 2b trials in 210 patients with an average reduction in pain of 50% and the fact it has no adverse side effects apart from bruising around the injection site and has also been used under the special access scheme by some 500 odd patients shows we should at very least be priced near 2 billion and possibly as high as 10 billion. It may take an offer from a pharma company for it to hit those heights but it is a high possibility of happening anytime soon. So much news to come too, it's going to be an exciting time to hold this company.